Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239328 · ClinicalTrials.gov registry record
A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer
A clinical trial, sponsored by University of Virginia.
- Completed
- Registry status
- 182
- Enrollment target
NCT02239328: Completed study, sponsored by University of Virginia.
NCT02239328 is a clinical trial that has completed, run by University of Virginia. The registered enrollment target is 182 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02239328 has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- 182 participants
- Enrollment target
Study Summary
This survey study is looking to determine if patient reported outcomes(using the PROMIS survey) will vary according to the presence of recurrent or metastatic lung or esophageal cancer.
Primary Outcome
Enrolled subjects with lung or esophageal cancer will be asked to complete an on-line (web-based) survey (PROMIS) using a computer. Most patients will only be asked to complete this survey once, but some patients will be asked to answer the questions a second or third time over a maximum five year period. The PROMIS assessment center was used to develop and administer patient reported outcomes (PROs) for each of these five cancer domains. PROMIS scores are continuous and range from 0-100. Total
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-07-01 |
What the finished NCT02239328 record still lists
NCT02239328 is an observational study that tracks outcomes without assigning an intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02239328 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02239328 about?
NCT02239328 is a clinical study titled "A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer". This survey study is looking to determine if patient reported outcomes(using the PROMIS survey) will vary according to the presence of recurrent or metastatic lung or esophageal cancer.
What is the current status of trial NCT02239328?
This trial is currently completed. The enrollment target is 182 participants. The study started on 2014-08. Estimated completion is 2017-07-01.
Who is sponsoring clinical trial NCT02239328?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia